Administered dose and tumor dose of bleomycin labeled with cobalt-57 in mice and men

D. Front, O. Israel, G. Iosilevsky, E. Even-Sapir, S. Ben-Haim, A. Frenkel, R. Ber, David M. Milstein, G. M. Kolodny

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Tumor concentrations of the chemotherapeutic drug, bleomycin, labeled with cobalt-57 (Co-bleo) were compared in mouse tumor models and in human lung tumors using quantitative single-photon emission computed tomography. Drug concentrations in histologically similar human tumors showed marked variability for the same injected dose (ID). Small cell carcinomas showed concentrations between 1.09 and 8.85 %ID/cc x 10-3 while non-small cell lung tumors showed a concentration variation between 0.36 and 6.75 %ID/cc x 10-3. In contrast to the situation in human tumors, uptake in mouse tumors showed only slight variability in animals with the same tumor model. EMT-6 tumors in mice showed at 6 hr significantly higher uptake of Co-bleo (p < 0.001) and significantly higher tumor-to-lung ratio (p < 0.001) when compared to murine fibrosarcomas. The EMT-6 tumors in contrast to the fibrosarcomas responded to bleomycin treatment in a dose dependent manner. The results indicate that while in mice the tumor dose closely follows the administered dose, in humans, the tumor dose and the tumor-to-lung ratio in the individual patient cannot be predicted from the administered dose.

Original languageEnglish (US)
Pages (from-to)1784-1790
Number of pages7
JournalJournal of Nuclear Medicine
Volume31
Issue number11
StatePublished - 1990
Externally publishedYes

Fingerprint

Bleomycin
Cobalt
Neoplasms
Lung
Fibrosarcoma
Small Cell Carcinoma
Single-Photon Emission-Computed Tomography
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Front, D., Israel, O., Iosilevsky, G., Even-Sapir, E., Ben-Haim, S., Frenkel, A., ... Kolodny, G. M. (1990). Administered dose and tumor dose of bleomycin labeled with cobalt-57 in mice and men. Journal of Nuclear Medicine, 31(11), 1784-1790.

Administered dose and tumor dose of bleomycin labeled with cobalt-57 in mice and men. / Front, D.; Israel, O.; Iosilevsky, G.; Even-Sapir, E.; Ben-Haim, S.; Frenkel, A.; Ber, R.; Milstein, David M.; Kolodny, G. M.

In: Journal of Nuclear Medicine, Vol. 31, No. 11, 1990, p. 1784-1790.

Research output: Contribution to journalArticle

Front, D, Israel, O, Iosilevsky, G, Even-Sapir, E, Ben-Haim, S, Frenkel, A, Ber, R, Milstein, DM & Kolodny, GM 1990, 'Administered dose and tumor dose of bleomycin labeled with cobalt-57 in mice and men', Journal of Nuclear Medicine, vol. 31, no. 11, pp. 1784-1790.
Front D, Israel O, Iosilevsky G, Even-Sapir E, Ben-Haim S, Frenkel A et al. Administered dose and tumor dose of bleomycin labeled with cobalt-57 in mice and men. Journal of Nuclear Medicine. 1990;31(11):1784-1790.
Front, D. ; Israel, O. ; Iosilevsky, G. ; Even-Sapir, E. ; Ben-Haim, S. ; Frenkel, A. ; Ber, R. ; Milstein, David M. ; Kolodny, G. M. / Administered dose and tumor dose of bleomycin labeled with cobalt-57 in mice and men. In: Journal of Nuclear Medicine. 1990 ; Vol. 31, No. 11. pp. 1784-1790.
@article{bbb48172e93d4792bb2b90e886fdce29,
title = "Administered dose and tumor dose of bleomycin labeled with cobalt-57 in mice and men",
abstract = "Tumor concentrations of the chemotherapeutic drug, bleomycin, labeled with cobalt-57 (Co-bleo) were compared in mouse tumor models and in human lung tumors using quantitative single-photon emission computed tomography. Drug concentrations in histologically similar human tumors showed marked variability for the same injected dose (ID). Small cell carcinomas showed concentrations between 1.09 and 8.85 {\%}ID/cc x 10-3 while non-small cell lung tumors showed a concentration variation between 0.36 and 6.75 {\%}ID/cc x 10-3. In contrast to the situation in human tumors, uptake in mouse tumors showed only slight variability in animals with the same tumor model. EMT-6 tumors in mice showed at 6 hr significantly higher uptake of Co-bleo (p < 0.001) and significantly higher tumor-to-lung ratio (p < 0.001) when compared to murine fibrosarcomas. The EMT-6 tumors in contrast to the fibrosarcomas responded to bleomycin treatment in a dose dependent manner. The results indicate that while in mice the tumor dose closely follows the administered dose, in humans, the tumor dose and the tumor-to-lung ratio in the individual patient cannot be predicted from the administered dose.",
author = "D. Front and O. Israel and G. Iosilevsky and E. Even-Sapir and S. Ben-Haim and A. Frenkel and R. Ber and Milstein, {David M.} and Kolodny, {G. M.}",
year = "1990",
language = "English (US)",
volume = "31",
pages = "1784--1790",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "11",

}

TY - JOUR

T1 - Administered dose and tumor dose of bleomycin labeled with cobalt-57 in mice and men

AU - Front, D.

AU - Israel, O.

AU - Iosilevsky, G.

AU - Even-Sapir, E.

AU - Ben-Haim, S.

AU - Frenkel, A.

AU - Ber, R.

AU - Milstein, David M.

AU - Kolodny, G. M.

PY - 1990

Y1 - 1990

N2 - Tumor concentrations of the chemotherapeutic drug, bleomycin, labeled with cobalt-57 (Co-bleo) were compared in mouse tumor models and in human lung tumors using quantitative single-photon emission computed tomography. Drug concentrations in histologically similar human tumors showed marked variability for the same injected dose (ID). Small cell carcinomas showed concentrations between 1.09 and 8.85 %ID/cc x 10-3 while non-small cell lung tumors showed a concentration variation between 0.36 and 6.75 %ID/cc x 10-3. In contrast to the situation in human tumors, uptake in mouse tumors showed only slight variability in animals with the same tumor model. EMT-6 tumors in mice showed at 6 hr significantly higher uptake of Co-bleo (p < 0.001) and significantly higher tumor-to-lung ratio (p < 0.001) when compared to murine fibrosarcomas. The EMT-6 tumors in contrast to the fibrosarcomas responded to bleomycin treatment in a dose dependent manner. The results indicate that while in mice the tumor dose closely follows the administered dose, in humans, the tumor dose and the tumor-to-lung ratio in the individual patient cannot be predicted from the administered dose.

AB - Tumor concentrations of the chemotherapeutic drug, bleomycin, labeled with cobalt-57 (Co-bleo) were compared in mouse tumor models and in human lung tumors using quantitative single-photon emission computed tomography. Drug concentrations in histologically similar human tumors showed marked variability for the same injected dose (ID). Small cell carcinomas showed concentrations between 1.09 and 8.85 %ID/cc x 10-3 while non-small cell lung tumors showed a concentration variation between 0.36 and 6.75 %ID/cc x 10-3. In contrast to the situation in human tumors, uptake in mouse tumors showed only slight variability in animals with the same tumor model. EMT-6 tumors in mice showed at 6 hr significantly higher uptake of Co-bleo (p < 0.001) and significantly higher tumor-to-lung ratio (p < 0.001) when compared to murine fibrosarcomas. The EMT-6 tumors in contrast to the fibrosarcomas responded to bleomycin treatment in a dose dependent manner. The results indicate that while in mice the tumor dose closely follows the administered dose, in humans, the tumor dose and the tumor-to-lung ratio in the individual patient cannot be predicted from the administered dose.

UR - http://www.scopus.com/inward/record.url?scp=0025026365&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025026365&partnerID=8YFLogxK

M3 - Article

VL - 31

SP - 1784

EP - 1790

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 11

ER -